Publication:
Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria

dc.contributor.authorF. Ezzeten_US
dc.contributor.authorM. Van Vugten_US
dc.contributor.authorF. Nostenen_US
dc.contributor.authorS. Looareesuwanen_US
dc.contributor.authorN. J. Whiteen_US
dc.contributor.otherNovartis International AGen_US
dc.contributor.otherShoklo Malaria Research Uniten_US
dc.contributor.otherAcademic Medical Centre, University of Amsterdamen_US
dc.contributor.otherThe Hospital for Tropical Diseases, Bangkoken_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherJohn Radcliffe Hospitalen_US
dc.date.accessioned2018-09-07T09:21:46Z
dc.date.available2018-09-07T09:21:46Z
dc.date.issued2000-03-01en_US
dc.description.abstractThe objective of this study was to conduct a prospective population pharmacokinetic and pharmacodynamic evaluation of lumefantrine during blinded comparisons of artemether-lumefantrine treatment regimens in uncomplicated multidrug-resistant falciparum malaria. Three combination regimens containing an average adult lumefantrine dose of 1,920 mg over 3 days (four doses) (regimen A) or 2,780 mg over 3 or 5 days (six doses) (regimen B or C, respectively) were given to 266 Thai patients. Detailed observations were obtained for 51 hospitalized adults, and sparse data were collected for 215 patients of all ages in a community setting. The population absorption half- life of lumefantrine was 4.5 h. The model-based median (5th and 95th percentiles) peak plasma lumefantrine concentrations were 6.2 (0.25 and 14.8) μg/ml after regimen A, 9.0 (1.1 and 19.8) μg/ml after regimen B, and 8 (1.4 and 17.4) μg/ml after regimen C. During acute malaria, there was marked variability in the fraction of drug absorbed by patients (coefficient of variation, 150%). The fraction increased considerably and variability fell with clinical recovery, largely because food intake was resumed; taking a normal meal close to drug administration increased oral bioavailability by 108% (90% confidence interval, 64 to 164) (P, 0.0001). The higher-dose regimens (B and C) gave 60 and 100% higher areas under the concentration-time curves (AUC), respectively, and thus longer durations for which plasma lumefantrine concentrations exceeded the putative in vivo MIC of 280 μg/ml (median for regimen B, 252 h; that for regimen C, 298 h; that for regimen A, 204 h [P, 0.0001]) and higher cure rates. Lumefantrine oral bioavailability is very dependent on food and is consequently poor in acute malaria but improves markedly with recovery. The high cure rates with the two six-dose regimens resulted from increased AUC and increased time at which lumefantrine concentrations were above the in vivo MIC.en_US
dc.identifier.citationAntimicrobial Agents and Chemotherapy. Vol.44, No.3 (2000), 697-704en_US
dc.identifier.doi10.1128/AAC.44.3.697-704.2000en_US
dc.identifier.issn00664804en_US
dc.identifier.other2-s2.0-0033998085en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/26276
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0033998085&origin=inwarden_US
dc.subjectMedicineen_US
dc.titlePharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malariaen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0033998085&origin=inwarden_US

Files

Collections